-
Je něco špatně v tomto záznamu ?
Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia
G. Manukyan, P. Turcsanyi, Z. Mikulkova, G. Gabcova, R. Urbanova, P. Gajdos, V. Smotkova Kraiczova, S. Zehnalova, T. Papajik, E. Kriegova,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NV16-32339A
MZ0
CEP - Centrální evidence projektů
- MeSH
- časové faktory MeSH
- CD4-pozitivní T-lymfocyty metabolismus patologie MeSH
- CD8-pozitivní T-lymfocyty metabolismus patologie MeSH
- chronická lymfatická leukemie * farmakoterapie metabolismus patologie MeSH
- HLA-DR antigeny biosyntéza MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové proteiny biosyntéza MeSH
- pyrazoly aplikace a dávkování MeSH
- pyrimidiny aplikace a dávkování MeSH
- regulace genové exprese u leukemie účinky léků MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisation of neoplastic cells in chronic lymphocytic leukemia (CLL) after the short-term and long-term administration of ibrutinib. We aimed to assess the influence of short-term and long-term ibrutinib treatment on the HLA-DR expression on CLL cells, T cells and monocytes. The immunophenotyping of CLL and immune cells in peripheral blood was performed on 16 high-risk CLL patients treated with ibrutinib. After early ibrutinib administration, the HLA-DR expression on CLL cells reduced (P = 0.032), accompanied by an increase in CLL cell counts in peripheral blood (P = 0.001). In vitro culturing of CLL cells with ibrutinib also revealed the reduction in the HLA-DR expression at protein and mRNA levels (P < 0.01). The decrease in HLA-DR on CLL cells after the first month was followed by the gradual increase of its expression by the 12th month (P = 0.001). A one-month follow-up resulted in elevated absolute counts of CD4+ (P = 0.002) and CD8+ (P < 0.001) T cells as well as CD4+ and CD8+ cells bearing HLA-DR (P < 0.01). The long-term administration of ibrutinib was associated with the increased numbers of CD4+ bearing HLA-DR (P = 0.006) and elevation of HLA-DR expression on all monocyte subsets (P ≤ 0.004). Our results provide the first evidence of the time-dependent immunomodulatory effect of ibrutinib on CLL and T cells and monocytes. The clinical consequences of time-dependent changes in HLA-DR expression in ibrutinib treated patients deserve further investigation.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028250
- 003
- CZ-PrNML
- 005
- 20190819115108.0
- 007
- ta
- 008
- 190813s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2018.08.006 $2 doi
- 035 __
- $a (PubMed)30149317
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Manukyan, Gayane $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic; Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology NAS RA, Yerevan, Armenia.
- 245 10
- $a Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia / $c G. Manukyan, P. Turcsanyi, Z. Mikulkova, G. Gabcova, R. Urbanova, P. Gajdos, V. Smotkova Kraiczova, S. Zehnalova, T. Papajik, E. Kriegova,
- 520 9_
- $a There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisation of neoplastic cells in chronic lymphocytic leukemia (CLL) after the short-term and long-term administration of ibrutinib. We aimed to assess the influence of short-term and long-term ibrutinib treatment on the HLA-DR expression on CLL cells, T cells and monocytes. The immunophenotyping of CLL and immune cells in peripheral blood was performed on 16 high-risk CLL patients treated with ibrutinib. After early ibrutinib administration, the HLA-DR expression on CLL cells reduced (P = 0.032), accompanied by an increase in CLL cell counts in peripheral blood (P = 0.001). In vitro culturing of CLL cells with ibrutinib also revealed the reduction in the HLA-DR expression at protein and mRNA levels (P < 0.01). The decrease in HLA-DR on CLL cells after the first month was followed by the gradual increase of its expression by the 12th month (P = 0.001). A one-month follow-up resulted in elevated absolute counts of CD4+ (P = 0.002) and CD8+ (P < 0.001) T cells as well as CD4+ and CD8+ cells bearing HLA-DR (P < 0.01). The long-term administration of ibrutinib was associated with the increased numbers of CD4+ bearing HLA-DR (P = 0.006) and elevation of HLA-DR expression on all monocyte subsets (P ≤ 0.004). Our results provide the first evidence of the time-dependent immunomodulatory effect of ibrutinib on CLL and T cells and monocytes. The clinical consequences of time-dependent changes in HLA-DR expression in ibrutinib treated patients deserve further investigation.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a CD4-pozitivní T-lymfocyty $x metabolismus $x patologie $7 D015496
- 650 _2
- $a CD8-pozitivní T-lymfocyty $x metabolismus $x patologie $7 D018414
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u leukemie $x účinky léků $7 D015973
- 650 _2
- $a HLA-DR antigeny $x biosyntéza $7 D006684
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chronická lymfatická leukemie $x farmakoterapie $x metabolismus $x patologie $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádorové proteiny $x biosyntéza $7 D009363
- 650 _2
- $a pyrazoly $x aplikace a dávkování $7 D011720
- 650 _2
- $a pyrimidiny $x aplikace a dávkování $7 D011743
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Turcsanyi, Peter $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Mikulkova, Zuzana $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Gabcova, Gabriela $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Urbanova, Renata $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Gajdos, Petr $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Czech Republic.
- 700 1_
- $a Smotkova Kraiczova, Veronika $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Zehnalova, Sarka $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Czech Republic.
- 700 1_
- $a Papajik, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Kriegova, Eva $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic. Electronic address: eva.kriegova@email.cz.
- 773 0_
- $w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 72, č. - (2018), s. 113-119
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30149317 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190819115342 $b ABA008
- 999 __
- $a ok $b bmc $g 1433399 $s 1066710
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 72 $c - $d 113-119 $e 20180810 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
- GRA __
- $a NV16-32339A $p MZ0
- LZP __
- $a Pubmed-20190813